- Home
- SPPL vs HOTH Comparison
SPPL vs HOTH Comparison
Compare SPPL & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPPL | HOTH |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.2M | 17.7M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SPPL | HOTH |
|---|---|---|
| Price | $2.18 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 8.0K | ★ 375.0K |
| Earning Date | 04-08-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.66 |
| 52 Week High | $7.00 | $2.12 |
Technical Indicators
Market Signals| Indicator | SPPL | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 38.98 |
| Support Level | N/A | $0.75 |
| Resistance Level | $3.58 | $1.12 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 21.90 | 2.95 |
Price Performance
Historical ComparisonAbout SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).